About: Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension
Creator	Arrigo, · Borghi, Claudio Cicero, F Ferri, Claudio Grassi, Guido Iaccarino, Guido Leonardo, · Massimo Volpe, · Minuz, Pietro Muiesan, Maria Mulatero, Paolo Mulè, Giuseppe Pucci, Giacomo Salvetti, Massimo Savoia, Carmine Sechi, Alberto
Source	Medline; PMC
abstract	Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin–Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present COVID-19 outbreak. Here we present the reasoned statement of the Italian Society of Hypertension to maintain ongoing antihypertensive treatments. Furthermore, the Italian Society of Hypertension presents its own initiative to investigate the issue using an online questionnaire to collect relevant data in human disease.
has issue date	2020-04-07(xsd:dateTime)
bibo:doi	10.1007/s40292-020-00380-3
bibo:pmid	32266708
has license	no-cc
sha1sum (hex)	31f3c18d51946fd9e1afcc4d24cb5454d17359ae
schema:url	https://doi.org/10.1007/s40292-020-00380-3
resource representing a document's title	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension
has PubMed Central identifier	PMC7138256
has PubMed identifier	32266708
schema:publication	High Blood Press Cardiovasc Prev
resource representing a document's body	covid:31f3c18d51946fd9e1afcc4d24cb5454d17359ae#body_text
is schema:about of	named entity 'Board' named entity 'Patients' named entity 'Statement' named entity 'Inhibition' named entity 'Nothing' named entity 'Cardiovascular diseases' named entity 'CLINICAL GUIDELINES' named entity 'Hypertension' named entity 'Cardiovascular' named entity 'kidney' named entity 'ARBs' named entity 'hypertensive' named entity 'infection' named entity 'cardiovascular disease' named entity 'infection' named entity 'ACE2' named entity 'ACE inhibitors' named entity 'COVID-19 disease' named entity 'ARBs' named entity 'membrane-bound' named entity 'angiotensin-converting enzyme' named entity 'ACE2' named entity 'ACE' named entity 'ACE2' named entity 'spread of the disease' named entity 'COVID' named entity 'COVID-19' named entity 'ACE' named entity 'receptor' named entity 'ACE' named entity 'upregulation' named entity 'SARS-CoV-2' named entity 'ACE inhibitors' named entity 'animal studies' named entity 'carboxypeptidase' named entity 'angiotensin II receptor type 1' named entity 'antihypertensive treatment' named entity 'ACE inhibitors' named entity 'ACE2' named entity 'lung' named entity 'Italian' named entity 'ARBs' named entity 'Angiotensin II' named entity 'Coronavirus' named entity 'COVID' named entity 'clinicaltrials.gov' named entity 'angiotensin II' named entity 'ARBs' named entity 'upregulation' named entity 'ARBs' named entity 'cardiovascular disease' named entity 'spike protein' named entity 'human lung' named entity 'SARS' named entity 'RAS' named entity 'ACE Inhibitors' named entity 'hypertension' named entity 'ACE2' named entity 'sepsis' named entity 'ACE2' named entity 'upregulation' named entity 'epidemic' named entity 'word of mouth' named entity 'enzyme' named entity 'ACE inhibitors' named entity 'attenuation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software